Takara Bio terminates the license agreement relating to Oncolytic Virus C-REV with Tasly Biopharmaceuticals, China August 4, 2020August 4, 2020 by / Share This.....LinkedinTwitterFacebookGoogleEmailRelated News: [Delayed]Takara Bio Announces Transfer of SAKIGAKE…Takara Bio Group Formulated “Medium-Term Management…Takara Bio Report 2022Takara Bio Report 2023FDA accepts supplemental Biologics License…U.S. Centers for Disease Control Guidance Includes…
